One of the easily accessible and most abundant live species present in the marine ecosystem, derivatives of seaweed are already known to have many medicinal-nutraceutical properties. “Several polysaccharides isolated from red and green seaweeds have been evaluated for its antiviral characteristics and found to have ability to inhibit the initial attachment of virus to the host cells which in turn effectively block the viral entry to human body,” said Ashish Jha, Suseela Mathew and CN Ravishankar from the CIFT in the study.
Carrageenan, a sulphated polysaccharide from red seaweed has already been tried as a therapeutic agent for respiratory illness like common cold, influenza virus H1N1. In view of its immense potential, they proposed that sulphated polysaccharide can be a potent molecule to fight against Covid pandemic, hence a candidate molecule to be studied against SARS-CoV-2.
In fact, the study holds importance in the context of India which has recently outlined an ambitious blueprint for the seaweed industry even as the Government in the Budget 2021-22 approved setting up of a multi-purpose seaweed park in Tamil Nadu.
While the seaweed can be potential candidate for an effective immune therapy to fight Covid-19, these ‘wonder plants of the sea’ are being used from being a good source of colloidal materials used as gelling agents, emulsifiers, stabilisers, in pharmaceutical, cosmetic and food products. Hence, a good source of livelihood for the coastal communities hit by climate change threats.